bluebird bio Reports Early Phase 3 Data

Shares of bluebird bio were off 5% pre-market Friday after the company unveiled early interim data from an ongoing phase 3 trial of its blood disorder gene therapy LentiGlobin in patients with beta-thalassemia. The company said a first patient achieved a normal level of hemoglobin in six months but added a follow-up on a second and third patient was not sufficient for total hemoglobin or days since last transfusion to be clinically relevant.

bluebird bio also said it presented new data from another study (HGB-205) evaluating LentiGlobin in patients with beta-thalassemia and severe sickle cell disease at the European Hematology Association in Paris, France. Commenting on the HGB-205 study, chief medical officer David Davidson said, “Results from this study to date demonstrate the potential for durable treatment effect of LentiGlobin, with stable HbAT87Q production through 3.5 years of follow-up and sustained clinical benefit.”